The Best Way to Use Ketamine - Episode 164

Join Dr. Jeffrey Gladden, Steve, Dr. Brent, and Andrea Turnipseed in this episode of the Gladden Longevity Podcast.  Dr. Brent Turnipseed, M.D., is the Co-Founder of Roots Behavioral Health and serves as their Medical Director. A board-certified psychiatrist with a deep interest in innovative approaches to providing behavioral healthcare, Brent sits on the Scientific Advisory Board for Ninnion Therapeutics, and he is the creator of all treatment protocols at Roots Behavioral Health. Andrea Turnipseed, LCSW, is Roots Behavioral Health's co-founder and serves as their Executive Director. Andrea has training and a background in adult mental health and has worked with clients in acute inpatient and outpatient psychiatric settings, facilitating both group and individual therapy. She is trained in providing Ketamine-Assisted Psychotherapy. In this episode, they talk about all things psychological health, the use of Ketamine-Assisted Psychotherapy to treat depression, lifestyle habits that will improve brain health and boost well-being, and how our digital habits affect our brain health. 

Listen to this episode to learn about making a 100 the new 30 and living beyond 120! 

 

Dr. Gladden introduces Dr. Brent and Andrea Turnipseed as they talk about all things about psychological health. (0:35) 

Andrea explains how they started as a traditional practice and how they found out that traditional medicine is not always working for their clients. (1:30) 

Brent notes that over one-third of clients were not seeing improvements with traditional medicine. (3:00) 

Brent shares that we are currently in a time when the paradigm is being questioned. (5:43) 

Brent reveals that staying on antidepressants and other similar medications changes the physiology of how brain chemistry works. (7:15) 

Brent points out that there are some genes that indicate whether a person will metabolize a medicine quickly or slowly. (9:20) 

Andrea discloses that they ask about patients' history and lifestyle when trying to help patients. (11:00) 

Dr. Gladden recalls having read that neuroinflammation is associated with depression. (14:00) 

Dr. Gladden says that neuroinflammation is interesting because aging comprises increasing mechanisms of inflammation. (16:10) 

Dr. Gladden refers to what he is currently doing at Gladden Longevity called Brain Frequency, which is a modified form of transcranial magnetic stimulation. (18:34) 

Brent brings up the observation that no one has really done a clinical trial in the last 20 years testing the effects of NAD. (20:32) 

Dr. Gladden advocates that if you are interested in improving the energetics of the neuron, then getting intracellular NAD is what you are going to be after. (21:59) 

Andrea talks about the effectiveness of ketamine and how about sixty percent of the time it works for people with treatment-resistant depression. (25:55) 

Andrea points out that people seem to open up a little bit more after taking ketamine, and it helps them open up better than traditional therapy. (29:00) 

Brent throws light on ketamine, its use, and its FDA approval status. (31:00) 

Brent says ketamine is an NMDA receptor antagonist. (33:00) 

Brent states t